Literature DB >> 12446777

Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex.

Shiann-Tarng Jou1, Nick Carpino, Yutaka Takahashi, Roland Piekorz, Jyh-Rong Chao, Neena Carpino, Demin Wang, James N Ihle.   

Abstract

Many receptor and nonreceptor tyrosine kinases activate phosphoinositide 3-kinases (PI3Ks). To assess the role of the delta isoform of the p110 catalytic subunit of PI3Ks, we derived enzyme-deficient mice. The mice are viable but have decreased numbers of mature B cells, a block in pro-B-cell differentiation, and a B1 B-cell deficiency. Both immunoglobulin M receptor-induced Ca(2+) flux and proliferation in response to B-cell mitogens are attenuated. Immunoglobulin levels are decreased substantially. The ability to respond to T-cell-independent antigens is markedly reduced, and the ability to respond to T-cell-dependent antigens is completely eliminated. Germinal center formation in the spleen in response to antigen stimulation is disrupted. These results define a nonredundant signaling pathway(s) utilizing the delta isoform of p110 PI3K for the development and function of B cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12446777      PMCID: PMC139888          DOI: 10.1128/MCB.22.24.8580-8591.2002

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  39 in total

1.  Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity.

Authors:  E M Schaeffer; J Debnath; G Yap; D McVicar; X C Liao; D R Littman; A Sher; H E Varmus; M J Lenardo; P L Schwartzberg
Journal:  Science       Date:  1999-04-23       Impact factor: 47.728

2.  Requirement for B cell linker protein (BLNK) in B cell development.

Authors:  R Pappu; A M Cheng; B Li; Q Gong; C Chiu; N Griffin; M White; B P Sleckman; A C Chan
Journal:  Science       Date:  1999-12-03       Impact factor: 47.728

3.  Impaired Fas response and autoimmunity in Pten+/- mice.

Authors:  A Di Cristofano; P Kotsi; Y F Peng; C Cordon-Cardo; K B Elkon; P P Pandolfi
Journal:  Science       Date:  1999-09-24       Impact factor: 47.728

4.  Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase.

Authors:  L Bi; I Okabe; D J Bernard; A Wynshaw-Boris; R L Nussbaum
Journal:  J Biol Chem       Date:  1999-04-16       Impact factor: 5.157

5.  Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells.

Authors:  R Moriggl; D J Topham; S Teglund; V Sexl; C McKay; D Wang; A Hoffmeyer; J van Deursen; M Y Sangster; K D Bunting; G C Grosveld; J N Ihle
Journal:  Immunity       Date:  1999-02       Impact factor: 31.745

6.  Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha.

Authors:  D A Fruman; S B Snapper; C M Yballe; L Davidson; J Y Yu; F W Alt; L C Cantley
Journal:  Science       Date:  1999-01-15       Impact factor: 47.728

7.  Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase.

Authors:  H Suzuki; Y Terauchi; M Fujiwara; S Aizawa; Y Yazaki; T Kadowaki; S Koyasu
Journal:  Science       Date:  1999-01-15       Impact factor: 47.728

8.  Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses.

Authors:  S Teglund; C McKay; E Schuetz; J M van Deursen; D Stravopodis; D Wang; M Brown; S Bodner; G Grosveld; J N Ihle
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

Review 9.  Phosphoinositide kinases.

Authors:  D A Fruman; R E Meyers; L C Cantley
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

10.  Qualitative regulation of B cell antigen receptor signaling by CD19: selective requirement for PI3-kinase activation, inositol-1,4,5-trisphosphate production and Ca2+ mobilization.

Authors:  A M Buhl; C M Pleiman; R C Rickert; J C Cambier
Journal:  J Exp Med       Date:  1997-12-01       Impact factor: 14.307

View more
  132 in total

Review 1.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

Review 2.  Control systems and decision making for antibody production.

Authors:  Christopher C Goodnow; Carola G Vinuesa; Katrina L Randall; Fabienne Mackay; Robert Brink
Journal:  Nat Immunol       Date:  2010-07-20       Impact factor: 25.606

Review 3.  Phosphatidylinositol 3 Kinase δ Inhibitors: Present and Future.

Authors:  Jennifer R Brown
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

4.  Biased binding of class IA phosphatidyl inositol 3-kinase subunits to inducible costimulator (CD278).

Authors:  Yenny Y Acosta; Maria Paz Zafra; Gloria Ojeda; Ilaria Seren Bernardone; Umberto Dianzani; Pilar Portolés; Jose M Rojo
Journal:  Cell Mol Life Sci       Date:  2010-12-28       Impact factor: 9.261

5.  Study on improving the selectivity of compounds that inhibit two PI3Ks (gamma and delta).

Authors:  Rong-Ren Kuang; Feng Qian; Zhong Li; Dong-Zhi Wei
Journal:  J Mol Model       Date:  2006-01-11       Impact factor: 1.810

6.  Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

Authors:  Marie Will; Alice Can Ran Qin; Weiyi Toy; Zhan Yao; Vanessa Rodrik-Outmezguine; Claudia Schneider; Xiaodong Huang; Prashant Monian; Xuejun Jiang; Elisa de Stanchina; José Baselga; Ningshu Liu; Sarat Chandarlapaty; Neal Rosen
Journal:  Cancer Discov       Date:  2014-01-16       Impact factor: 39.397

7.  Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.

Authors:  Barbara Geering; Pedro R Cutillas; Gemma Nock; Severine I Gharbi; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

8.  PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.

Authors:  Dalya R Soond; Elisa Bjørgo; Kristine Moltu; Verity Q Dale; Daniel T Patton; Knut Martin Torgersen; Fiona Galleway; Breda Twomey; Jonathan Clark; J S Hill Gaston; Kjetil Taskén; Peter Bunyard; Klaus Okkenhaug
Journal:  Blood       Date:  2010-01-15       Impact factor: 22.113

9.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

10.  Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

Authors:  Klemens Hoegenauer; Nicolas Soldermann; Frédéric Stauffer; Pascal Furet; Nadege Graveleau; Alexander B Smith; Christina Hebach; Gregory J Hollingworth; Ian Lewis; Sascha Gutmann; Gabriele Rummel; Mark Knapp; Romain M Wolf; Joachim Blanz; Roland Feifel; Christoph Burkhart; Frédéric Zécri
Journal:  ACS Med Chem Lett       Date:  2016-06-02       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.